AMPAC Fine Chemicals (“AFC”), a leading US-based Contract Development and Manufacturing Organization (“CDMO”), today announced its sale to SK Holdings (“SK”), an investment holding company of SK Group (South Korea). This acquisition is the largest M&A transaction announced in the Korean pharmaceutical industry. Since February 2014, AFC has been owned by H.I.G. Capital (“H.I.G.”), a […]
AMPAC Fine Chemicals (“AFC”), a leading US-based Contract Development and Manufacturing Organization (“CDMO”), today announced its sale to SK Holdings (“SK”), an investment holding company of SK Group (South Korea). This acquisition is the largest M&A transaction announced in the Korean pharmaceutical industry.
Since February 2014, AFC has been owned by H.I.G. Capital (“H.I.G.”), a global private equity firm. Under H.I.G.’s ownership, AFC expanded the manufacturing footprint at Rancho Cordova, CA facility, started AMPAC Analytical, acquired a state-of-the art plant in Petersburg, VA, substantially enhanced its product pipeline, and delivered industry-leading growth every year since acquisition.
SK is purchasing AFC due to its unique capabilities, world class facilities, excellent reputation, outstanding people and great growth potential. AFC is SK’s sole CDMO operation in the US and will play a crucial part in SK’s development as a global leader in pharmaceuticals manufacturing.
“Pharmaceuticals is one of SK Holdings’ key pillars of growth and the acquisition of AFC is an important step towards becoming a global player in the market,” said Donghyun Jang, President and Chief Executive Officer of SK Holdings. Mr. Jang added, “AFC’s development and manufacturing capabilities and outstanding regulatory track record are an excellent complement to SK.”
Aslam Malik, Chief Executive Officer of AFC, added, “We are excited to join SK Holdings. SK and AFC are highly complementary and with SK’s strong presence in Europe and Asia, we will be able to provide our customers a much broader portfolio of offerings including a global supply chain. Together we will achieve SK’s goal of becoming a global, top-tier CDMO.”
AMPAC Fine Chemicals (“AFC”), a leading US-based Contract Development and Manufacturing Organization (“CDMO”), today announced its sale to SK Holdings (“SK”), an investment holding company of SK Group (South Korea). This acquisition is the largest M&A transaction announced in the Korean pharmaceutical industry.
Since February 2014, AFC has been owned by H.I.G. Capital (“H.I.G.”), a global private equity firm. Under H.I.G.’s ownership, AFC expanded the manufacturing footprint at Rancho Cordova, CA facility, started AMPAC Analytical, acquired a state-of-the art plant in Petersburg, VA, substantially enhanced its product pipeline, and delivered industry-leading growth every year since acquisition.
SK is purchasing AFC due to its unique capabilities, world class facilities, excellent reputation, outstanding people and great growth potential. AFC is SK’s sole CDMO operation in the US and will play a crucial part in SK’s development as a global leader in pharmaceuticals manufacturing.
“Pharmaceuticals is one of SK Holdings’ key pillars of growth and the acquisition of AFC is an important step towards becoming a global player in the market,” said Donghyun Jang, President and Chief Executive Officer of SK Holdings. Mr. Jang added, “AFC’s development and manufacturing capabilities and outstanding regulatory track record are an excellent complement to SK.”
Aslam Malik, Chief Executive Officer of AFC, added, “We are excited to join SK Holdings. SK and AFC are highly complementary and with SK’s strong presence in Europe and Asia, we will be able to provide our customers a much broader portfolio of offerings including a global supply chain. Together we will achieve SK’s goal of becoming a global, top-tier CDMO.”
